BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1277 related articles for article (PubMed ID: 32873455)

  • 1. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
    Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
    Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
    Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
    Ljunggren M; Nordenvall C; Palmer G
    Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
    Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
    Trials; 2010 May; 11():62. PubMed ID: 20500867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 10. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 11. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
    JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
    World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC.
    Simkens GA; van Oudheusden TR; Nieboer D; Steyerberg EW; Rutten HJ; Luyer MD; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2016 Dec; 23(13):4214-4221. PubMed ID: 27027308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
    Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
    Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
    Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
    Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis-Related Markers and Prognosis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer.
    de Cuba EM; de Hingh IH; Sluiter NR; Kwakman R; Coupé VM; Beliën JA; Verwaal VJ; Meijerink WJ; Delis-van Diemen PM; Bonjer HJ; Meijer GA; Te Velde EA
    Ann Surg Oncol; 2016 May; 23(5):1601-8. PubMed ID: 26727921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
    Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
    BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.